Consolidated Statements of Changes in Stockholders' Equity (USD $)
|
Total
|
JSOP Awards [Member]
|
SymbioTec GmbH [Member]
|
Serum Institute of India Limited [Member]
|
Common Stock [Member]
|
Common Stock [Member]
JSOP Awards [Member]
|
Common Stock [Member]
SymbioTec GmbH [Member]
|
Common Stock [Member]
Serum Institute of India Limited [Member]
|
Additional Paid-in Capital [Member]
|
Additional Paid-in Capital [Member]
JSOP Awards [Member]
|
Additional Paid-in Capital [Member]
SymbioTec GmbH [Member]
|
Additional Paid-in Capital [Member]
Serum Institute of India Limited [Member]
|
Retained Earnings [Member]
|
Accumulated Other Comprehensive Income (Loss) [Member]
|
Treasury Stock [Member]
|
Treasury Stock [Member]
JSOP Awards [Member]
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beginning Balance at Dec. 31, 2011 | $ 14,803,804 | $ 922,343 | $ 58,124,439 | $ (43,399,413) | $ (254,903) | $ (588,662) | ||||||||||
Beginning Balance, Shares at Dec. 31, 2011 | 92,234,321 | |||||||||||||||
Exercise of stock options | 709 | 195 | 514 | |||||||||||||
Exercise of stock options, Shares | 19,535 | |||||||||||||||
Issuance of common stock | 61,751 | 9,258,326 | 1,472,155 | 89,863 | 256,000 | 36,800 | 4,664,406 | 9,002,326 | 1,435,355 | (4,692,518) | ||||||
Issuance of common stock, Shares | 8,986,281 | 25,600,000 | 3,680,000 | |||||||||||||
Share-based compensation | 339,780 | 339,780 | ||||||||||||||
Net loss | (6,328,340) | (6,328,340) | ||||||||||||||
Foreign currency translation | 1,170,501 | 1,170,501 | ||||||||||||||
Ending Balance at Dec. 31, 2012 | 20,778,686 | 1,305,201 | 73,566,820 | (49,727,753) | 915,598 | (5,281,180) | ||||||||||
Ending Balance, Shares at Dec. 31, 2012 | 130,520,137 | |||||||||||||||
Exercise of stock options | 2,090 | 554 | 1,536 | |||||||||||||
Exercise of stock options, Shares | 55,379 | |||||||||||||||
Share-based compensation | 431,504 | 431,504 | ||||||||||||||
Net loss | (8,579,246) | (8,579,246) | ||||||||||||||
Foreign currency translation | (15,344) | (15,344) | ||||||||||||||
Ending Balance at Dec. 31, 2013 | $ 12,617,690 | $ 1,305,755 | $ 73,999,860 | $ (58,306,999) | $ 900,254 | $ (5,281,180) | ||||||||||
Ending Balance, Shares at Dec. 31, 2013 | 130,575,516 |